TY - GEN
T1 - Transmembrane scf nanodiscs enhance revascularization in ischemia and induce cd34-/cd133+ endothelial progenitor cells
AU - Takematsu, Eri
AU - Auster, Jeff
AU - Singh, Aditya
AU - Chen, Po Chih
AU - Canga, Sophia
AU - Degroot, Andre
AU - Sherman, Michael
AU - Stachowiak, Jeanne
AU - Dunn, Andrew K.
AU - Baker, Aaron B.
N1 - Publisher Copyright:
© 2019 Omnipress - All rights reserved.
PY - 2019
Y1 - 2019
N2 - Statement of Purpose: Diabetes mellitus affects approximately 350 million people, leading to the death of about 4.6 million people in the world. 20-30% of patients with diabetes develop peripheral vascular disease (PVD), among which 25% require amputation, causing a decrease in quality of life. Standard cares of PVD such as stenting are often invasive, so demand for noninvasive treatment is rising. Method that may fulfill such needs is a protein therapy that revives the blood flow in ischemic area. Previously, we explored the use of transmembrane stem cell factor (tmSCF) as a therapeutic protein for restoring blood flow at ischemic area. We found a significant higher blood flow recovery after hind limb ischemia surgery when treated with tmSCF proteoliposomes (PLs) and nanodiscs (NDs). In this research, we hypothesize that tmSCFPLs/NDs stimulate bone marrow cells (BMCs) and increase the CD34-CD133+ subpopulation of endothelial progenitor cells (EPCs). Moreover, enhanced mobilization of EPCs to peripheral blood (PB) was confirmed when treated with tmSCFNDs.
AB - Statement of Purpose: Diabetes mellitus affects approximately 350 million people, leading to the death of about 4.6 million people in the world. 20-30% of patients with diabetes develop peripheral vascular disease (PVD), among which 25% require amputation, causing a decrease in quality of life. Standard cares of PVD such as stenting are often invasive, so demand for noninvasive treatment is rising. Method that may fulfill such needs is a protein therapy that revives the blood flow in ischemic area. Previously, we explored the use of transmembrane stem cell factor (tmSCF) as a therapeutic protein for restoring blood flow at ischemic area. We found a significant higher blood flow recovery after hind limb ischemia surgery when treated with tmSCF proteoliposomes (PLs) and nanodiscs (NDs). In this research, we hypothesize that tmSCFPLs/NDs stimulate bone marrow cells (BMCs) and increase the CD34-CD133+ subpopulation of endothelial progenitor cells (EPCs). Moreover, enhanced mobilization of EPCs to peripheral blood (PB) was confirmed when treated with tmSCFNDs.
UR - http://www.scopus.com/inward/record.url?scp=85065410206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065410206&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:85065410206
T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
SP - 266
BT - Society for Biomaterials Annual Meeting and Exposition 2019
PB - Society for Biomaterials
T2 - 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
Y2 - 3 April 2019 through 6 April 2019
ER -